Clinical Report: Correction to Funding and Conflict Disclosures

Overview

A correction was issued for the Original Investigation “Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan,” published August 29, 2026. The correction addresses an incorrect grant identifier in the Funding/Support statement and a typographical error in the Conflict of Interest disclosures; no further details are provided in the supplied material.

Background

Periprocedural mortality after elective atrial fibrillation ablation is the subject of the corrected investigation. Funding and conflict-of-interest disclosures provide information about research support and potential competing interests. The supplied correction context identifies errors in these disclosures but does not describe changes to the investigation’s methods, results, or conclusions. Contemporary AHA/ACC performance and quality measures include procedure-related metrics and catheter-ablation complications.

Data Highlights

The supplied correction context reports no numerical or trial data. It identifies two disclosure corrections: an incorrect grant identifier under Funding/Support and a typographical error in the Conflict of Interest section.

Key Findings

• The correction concerns the Original Investigation “Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan.”
• The original investigation appeared on August 29, 2026, according to the supplied context.
• The Funding/Support statement contained an incorrect grant identifier.
• The Conflict of Interest section contained a typographical mistake.
• The supplied material does not specify the corrected grant identifier or the corrected wording.
• The 2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation include procedure-related metrics and catheter-ablation complications.

Clinical Implications

The supplied correction concerns disclosure text and does not report changes to clinical findings or recommendations. The 2026 AHA/ACC measures provide a related framework for procedure-related metrics and complication reporting, but the supplied material does not link those measures to the correction.

Conclusion

The correction amends the funding identifier and a typographical error in the conflict disclosures for the Japanese elective AF ablation mortality investigation. The supplied information does not describe any effect on the study’s clinical results.

Related Resources & Content

1. JAMA Network Open, 2026 — Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan
2. American College of Cardiology/American Heart Association Joint Committee on Performance Measures, 2026 — 2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation
3. ASCO Publications — Author Correction
4. ASCO Publications — Errata
5. ASCO Publications — Reply to C. Ren et al
6. ASCO Publications — Reply to C. Ren et al
7. Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan
8. 2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation
9. 2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures
10. Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study | Nature Medicine
11. Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan | Cardiology | JAMA Network Open | JAMA Network